Epirubicin

Metastatic Colon Cancer

Asha NayakPhase 1/2Dormant

CCC

50/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 37/ 100
Competitive Position: 89/ 100

Competitive context

15 Active assets in the Metastatic Colon Cancer cohort.

Asset / Sponsor	Phase	Rating
Fruquintinib Peking University	Phase 3	BBB
Adebrelimab Sapience Therapeutics	Phase 3	BB
Cetuximab Shanghai 6th People's Hospital	Phase 3	BB
PANITUMUMAB University of Campania Luigi Vanvitelli	Phase 2	BB
Nivolumab Massachusetts General Hospital	Phase 3	B

View all 28 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

74 / 100

Lung Non-Small Cell Squamous CarcinomaDormant

BBB

Indicative ·

72 / 100

Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.